Alnylam Pharmaceuticals, Inc. vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| ALNY | JNJ | |
|---|---|---|
| Market Cap | $31.88 billion | $651.20 billion |
| Revenue (TTM) | $4.80 billion | $97.93 billion |
| Net Income (TTM) | $733.11 million | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| ALNY | JNJ | |
|---|---|---|
| P/E Ratio | 44.57 | 31.51 |
| Price / Book | 23.54 | 7.66 |
| Price / Sales | 6.64 | 6.65 |
JNJ leads on 2 of 3 valuation factors.
Profitability
| ALNY | JNJ | |
|---|---|---|
| Net Margin | 15.26% | 21.48% |
| Return on Equity | 54.14% | 24.76% |
ALNY and JNJ split the profitability factors evenly.
Dividend
| ALNY | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.97% |
| Payout Ratio | — | 62.18 |
ALNY and JNJ split the dividend factors evenly.
Risk & Sentiment
| ALNY | JNJ | |
|---|---|---|
| Short Interest | 4.32% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALNY overview, ALNY financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.